InvestorsHub Logo
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

Re: None

Thursday, 08/25/2011 4:39:51 PM

Thursday, August 25, 2011 4:39:51 PM

Post# of 145
DYAX $1.28 up a bit on its competitor's aproval.

FDA Approves Shire's Treatment For Swelling Disorder
11:14a ET August 25, 2011 (Dow Jones)
FDA Approves Shire's Treatment For Swelling Disorder
DOW JONES NEWSWIRES

Shire PLC's (SHPGY, SHP.LN) treatment for a rare swelling disorder was approved by the U.S. Food and Drug Administration.
The drug, Firazyr, is the third drug approved in the U.S. to treat attacks of a rare condition called hereditary angioedema, according to the FDA.
Firazyr is the first on-demand treatment for hereditary agiodema that patients can inject themselves when they feel an attack coming on, instead of seeking a health-care professional. This rare disorder is a potentially fatal condition that causes severe swelling in the hands and feet, gastrointestinal tract and upper airway.
The other FDA approved treatments are CSL Behring's Berinert to treat facial and abdominal attacks of the condition, and Dyax Corp.'s (DYAX) Kalbitor to treat acute attacks in patients ages 16 years and older.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com